M J Roobol

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint The use of nomograms in the detection of prostate cancer
    M J Roobol
    Department of Urology, Erasmus Medical Centre Rotterdam, 3000 CA Rotterdam, The Netherlands
    Prostate 66:1266-7. 2006
  2. ncbi request reprint International perspectives on screening
    Monique J Roobol
    Department of Urology, Erasmus University Medical Center, PO Box 2040, Rotterdam 3000 CA, The Netherlands Electronic address
    Urol Clin North Am 41:237-47. 2014
  3. doi request reprint Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer
    Monique J Roobol
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Eur Urol 64:530-9. 2013
  4. doi request reprint The prostate-specific antigen test
    Monique J Roobol
    Erasmus University Medical Centre, Department of Urology, Rotterdam, The Netherlands
    Expert Opin Med Diagn 7:423-6. 2013
  5. ncbi request reprint A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam
    Monique J Roobol
    Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Eur Urol 63:627-33. 2013
  6. doi request reprint Risk stratification in prostate cancer screening
    Monique J Roobol
    Department of Urology, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
    Nat Rev Urol 10:38-48. 2013
  7. pmc Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group
    Monique J Roobol
    Department of Urology, Erasmus University Medical Centre, P O Box 2010, 3000 CA, Rotterdam, The Netherlands
    World J Urol 30:149-55. 2012
  8. ncbi request reprint Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators
    Monique J Roobol
    Erasmus University Medical Centre, Department of Urology, Rotterdam, The Netherlands
    Eur Urol 61:577-83. 2012
  9. ncbi request reprint A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam)
    Monique J Roobol
    Department of Urology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Prostate 66:604-12. 2006
  10. doi request reprint Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100)
    Monique J Roobol
    Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 58:893-9. 2010

Collaborators

Detail Information

Publications97

  1. ncbi request reprint The use of nomograms in the detection of prostate cancer
    M J Roobol
    Department of Urology, Erasmus Medical Centre Rotterdam, 3000 CA Rotterdam, The Netherlands
    Prostate 66:1266-7. 2006
  2. ncbi request reprint International perspectives on screening
    Monique J Roobol
    Department of Urology, Erasmus University Medical Center, PO Box 2040, Rotterdam 3000 CA, The Netherlands Electronic address
    Urol Clin North Am 41:237-47. 2014
    ..Because cancer, especially prostate cancer, is predominantly a disease of the elderly, increases in the number of older people will lead to more cases of cancer, even if current incidence rates remain the same...
  3. doi request reprint Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer
    Monique J Roobol
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Eur Urol 64:530-9. 2013
    ..Evidence from randomized trials on the effects of screening for prostate cancer (PCa) on disease-specific mortality accumulates slowly with increasing follow-up...
  4. doi request reprint The prostate-specific antigen test
    Monique J Roobol
    Erasmus University Medical Centre, Department of Urology, Rotterdam, The Netherlands
    Expert Opin Med Diagn 7:423-6. 2013
    ..What we must do is use the test as wisely as is currently possible and inform men, who want to be tested, in a balanced way about harms and potential benefits. ..
  5. ncbi request reprint A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam
    Monique J Roobol
    Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Eur Urol 63:627-33. 2013
    ..Inconclusive test results often occur after prostate-specific antigen (PSA)-based screening for prostate cancer (PCa), leading to uncertainty on whether, how, and when to repeat testing...
  6. doi request reprint Risk stratification in prostate cancer screening
    Monique J Roobol
    Department of Urology, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
    Nat Rev Urol 10:38-48. 2013
    ..A risk-adapted approach is needed, whereby PSA testing is tailored to individual risk...
  7. pmc Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group
    Monique J Roobol
    Department of Urology, Erasmus University Medical Centre, P O Box 2010, 3000 CA, Rotterdam, The Netherlands
    World J Urol 30:149-55. 2012
    ..To compare the predictive performance and potential clinical usefulness of risk calculators of the European Randomized Study of Screening for Prostate Cancer (ERSPC RC) with and without information on prostate volume...
  8. ncbi request reprint Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators
    Monique J Roobol
    Erasmus University Medical Centre, Department of Urology, Rotterdam, The Netherlands
    Eur Urol 61:577-83. 2012
    ..The European Randomized Study of Screening for Prostate Cancer (ERSPC) risk calculators (RCs) are validated tools for prostate cancer (PCa) risk assessment and include prostate volume (PV) data from transrectal ultrasound (TRUS)...
  9. ncbi request reprint A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam)
    Monique J Roobol
    Department of Urology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Prostate 66:604-12. 2006
    ..The identification of predictors for prostate biopsy outcome at two screening rounds using a PSA>or=3.0 ng/ml as biopsy indication...
  10. doi request reprint Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100)
    Monique J Roobol
    Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 58:893-9. 2010
    ..Therefore a high PCA3 score should result in a high positive predictive value (PPV) and specificity for a positive biopsy...
  11. doi request reprint Tumour markers in prostate cancer III: biomarkers in urine
    Monique J Roobol
    Erasmus MC, University Medical Centre, Department of Urology, Rotterdam, The Netherlands
    Acta Oncol 50:85-9. 2011
    ..Protein-based, DNA-based and RNA-based urine biomarkers have been developed and tested...
  12. ncbi request reprint The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC)
    M J Roobol
    Department of Urology, Erasmus Medical Centre Rotterdam, The Netherlands
    Prostate 67:439-46. 2007
    ....
  13. doi request reprint Contemporary role of prostate cancer gene 3 in the management of prostate cancer
    Monique J Roobol
    Erasmus University Medical Centre, Rotterdam, The Netherlands
    Curr Opin Urol 21:225-9. 2011
    ..Within this context the role of the prostate cancer gene 3 (PCA3) test is evaluated...
  14. ncbi request reprint Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam)
    Monique J Roobol
    Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands
    Urology 65:343-6. 2005
    ..Recently, it has been proposed to determine the rescreening interval relative to the initial prostate-specific antigen (PSA) level and possibly to extend the rescreening interval up to 5 years...
  15. doi request reprint A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer
    Monique J Roobol
    Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Eur Urol 57:79-85. 2010
    ..Screening for prostate cancer (PC) is controversial due to uncertainties about its efficiency...
  16. ncbi request reprint Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)
    Monique J Roobol
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    Eur Urol 56:584-91. 2009
    ..This effect may be diluted by nonattendance in men randomised to the screening arm and contamination in men randomised to the control arm...
  17. ncbi request reprint Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands)
    M J Roobol
    Erasmus Medical Centre, Department of Urology, Rotterdam, The Netherlands
    BJU Int 92:48-54. 2003
    ....
  18. ncbi request reprint European Randomized Study of Screening for Prostate Cancer: achievements and presentation
    M J Roobol
    BJU Int 92:117-22. 2003
  19. doi request reprint Algorithms, nomograms and the detection of indolent prostate cancer
    Monique J Roobol
    Department of Urology, Erasmus Medical Center, P O Box 2040, Room NH 224, 3000 CA, Rotterdam, Netherlands
    World J Urol 26:423-9. 2008
    ..Prostate cancer is the most commonly diagnosed cancer in men. However, only about 12% of the men diagnosed with prostate cancer will die of their disease...
  20. ncbi request reprint Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project)
    M J Roobol
    Erasmus Medical Centre, Department of Urology and Pathology, Rotterdam, The Netherlands
    Urol Oncol 28:686-90. 2010
    ..Early detection can only be beneficial regarding mortality if the high risk cancers are recognized and treated at a localized stage...
  21. ncbi request reprint Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam
    Monique J Roobol
    Department of Urology, Erasmus Medical Centre, Rm NH 224, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Natl Cancer Inst 99:1296-303. 2007
    ..Variations in the screening algorithm, such as the interval between screening rounds, likely influence the morbidity, mortality, and quality of life of the screened population...
  22. ncbi request reprint Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test
    Monique J Roobol
    Erasmus MC, University Medical Centre, Department of Urology, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Eur Urol 58:475-81. 2010
    ..The performance characteristics of serum prostate-specific antigen (PSA) as a diagnostic test for prostate cancer (PCa) are poor. The performance of the PCa antigen 3 (PCA3) gene as a primary diagnostic is unknown...
  23. ncbi request reprint Screening and prostate-cancer mortality in a randomized European study
    Fritz H Schroder
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    N Engl J Med 360:1320-8. 2009
    ..The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer...
  24. ncbi request reprint Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam
    Rene Raaijmakers
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Urology 63:316-20. 2004
    ....
  25. pmc Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors
    E M Wever
    Department of Public Health, Erasmus Medical Center, P O Box 2040, Rotterdam, 3000, CA, The Netherlands
    Br J Cancer 108:1971-7. 2013
    ..We quantified how the benefits and harms of immediate treatment vary according to the prognostic factors of clinical T-stage, Gleason score, and patient age...
  26. ncbi request reprint Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM)
    M J Roobol
    Department of Urology, Erasmus Medical Centre Rotterdam, Netherlands Institute for Health Sciences, Rotterdam, The Netherlands
    Urology 63:309-13; discussion 313-5. 2004
    ..0 ng/mL or less. Digital rectal examination and/or transrectal ultrasonography have been used as screening tools at these low PSA levels, but this approach is not very efficient...
  27. ncbi request reprint No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam)
    M J Roobol
    Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands
    Urology 63:892-7; discussion 897-9. 2004
    ..The ERSPC offers the opportunity to study the yield of repeat biopsies after 4 years in men who had negative sextant biopsies and a prostate-specific antigen (PSA) level of 4.0 mg/mL or more at the first screening round...
  28. ncbi request reprint A more advanced clinical stage is positively correlated with an increased prostate cancer detection rate
    Monique J Roobol
    Department of Urology, Dijkzigt Academic Hospital, Rotterdam, The Netherlands
    Urology 59:91-6. 2002
    ..A suspicious digital rectal examination (DRE) and/or a suspicious transrectal ultrasound (TRUS) investigation increases the likelihood of prostate cancer given a certain prostate-specific antigen level...
  29. ncbi request reprint Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram
    E W Steyerberg
    Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Urol 177:107-12; discussion 112. 2007
    ..Statistical models have been proposed to predict indolent cancer. We validated and updated model predictions for a screening setting...
  30. ncbi request reprint Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 50:475-82. 2006
    ..Our knowledge about which prostate cancers are life threatening and which are not is limited. Thus, for ethical, medical, and economic reasons we need to define which patients can be managed by active surveillance...
  31. ncbi request reprint Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer
    Theodorus H van der Kwast
    Department of Pathology and Urology, Erasmus Medical Center, Rotterdam, The Netherlands, and Centro per la Studio e la Prevenzione Oncologica, University of Florence, Italy
    Int J Cancer 118:2538-42. 2006
    ..e. 507/10,000 men). Variations in detection rates among screening centers related among others to biopsy compliance and age range...
  32. ncbi request reprint 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam
    Fritz H Schroder
    Department of Urology, Erasmus University Rotterdam, The Netherlands
    J Urol 174:489-94; discussion 493-4. 2005
    ..The present study evaluates the predictive value of a prostate specific antigen (PSA) increase to PSA 3.0 ng/ml or greater in a 4-year period in men who present with low PSA values (less than 3.0 ng/ml) at first screen...
  33. ncbi request reprint Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a
    J A M J L Janssen
    Department of Internal Medicine, Room D 436, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:4391-6. 2004
    ..In addition, our results indicate that the endocrine IGF-I system is not directly involved in the growth of the early stages of prostate cancer...
  34. doi request reprint The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer
    C Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 68:985-93. 2008
    ....
  35. pmc Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer
    E A M Heijnsdijk
    Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Br J Cancer 101:1833-8. 2009
    ..Overdetection and overtreatment are substantial unfavourable side effects with consequent healthcare costs. In this study the effects of introducing widespread PSA screening is evaluated...
  36. ncbi request reprint Consistency of prostate cancer grading results in screened populations across Europe
    T H Van der Kwast
    Department of Pathology, Josephine Nefkens Institute, Erasmus Medical Center, Rotterdam, The Netherlands
    BJU Int 92:88-91. 2003
    ..Currently, tumour stage and grade in prostatectomy specimens represent the most predictive variables for biological behaviour. In prostate needle biopsies the tumour grade is a strong factor for deciding therapy...
  37. doi request reprint Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam)
    Melissa Kerkhof
    Department of Urology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Int J Cancer 127:2639-44. 2010
    ..In the population of ERSPC Rotterdam (N = 42,376 men), screening reduces the risk to be diagnosed with metastatic prostate cancer considerably on population level, an effect which is even more pronounced in men who are in fact screened...
  38. ncbi request reprint Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening
    Renske Postma
    Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 52:89-97. 2007
    ..To evaluate the features, rates, and characteristics of prostate cancer detected during two subsequent screening rounds...
  39. pmc Patients' and urologists' preferences for prostate cancer treatment: a discrete choice experiment
    E W de Bekker-Grob
    Department of Public Health, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands
    Br J Cancer 109:633-40. 2013
    ..Patients' preferences are important for shared decision making. Therefore, we investigated patients' and urologists' preferences for treatment alternatives for early prostate cancer (PC)...
  40. ncbi request reprint The effect of study arm on prostate cancer treatment in the large screening trial ERSPC
    Tineke Wolters
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Int J Cancer 126:2387-93. 2010
    ..Therefore, differences in treatment between arms are unlikely to play a major role in the interpretation of the results of the ERSPC...
  41. doi request reprint Do anxiety and distress increase during active surveillance for low risk prostate cancer?
    Roderick C N van den Bergh
    Erasmus Medical Center, Rotterdam, The Netherlands
    J Urol 183:1786-91. 2010
    ..Anxiety and distress may be present in patients with low risk prostate cancer who are on active surveillance. This may be a reason to discontinue active surveillance...
  42. doi request reprint Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit
    Pim J van Leeuwen
    Erasmus University Medical Centre, Rotterdam, The Netherlands
    Eur J Cancer 46:377-83. 2010
    ..To estimate the benefits of prostate-specific antigen (PSA) screening on prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations with a well-defined difference in intensity of screening...
  43. ncbi request reprint Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study
    Roderick C N van den Bergh
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    BJU Int 105:956-62. 2010
    ....
  44. doi request reprint Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer
    Tineke Wolters
    Department of Pathology, Erasmus MC, Rotterdam, The Netherlands Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 57:821-9. 2010
    ..In addition, tumour volume might be of value in substaging of pathologic tumour stage (pT2) prostate cancer (PCa)...
  45. ncbi request reprint Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review
    Roderick C N van den Bergh
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 54:505-16. 2008
    ..The kinetics of prostate specific antigen (PSA) are generally assumed to be indicative of tumour progression and are therefore used in clinical decision-making in men on active surveillance for early prostate cancer...
  46. doi request reprint Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies
    Fritz H Schroder
    Department of Urology, Erasmus MC, University Medical Center, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Eur Urol 57:256-66. 2010
    ..The appropriate way of biopsying a prostate remains controversial. Is sextant biopsy still adequate with repeat screening?..
  47. pmc PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making
    Lionne D F Venderbos
    Department of Urology, Erasmus MC, University Medical Centre, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Asian J Androl 13:219-24. 2011
    ..Now, as the results of three major screening studies have been presented and the downsides of screening are becoming better understood, informed choice is becoming more relevant...
  48. doi request reprint Disease-specific mortality may underestimate the total effect of prostate cancer screening
    Pim J van Leeuwen
    Erasmus University Medical Centre, Rotterdam, The Netherlands
    J Med Screen 17:204-10. 2010
    ..To study the difference between the disease-specific and excess mortality rate in the European Randomized Study of Screening for Prostate Cancer section Rotterdam...
  49. doi request reprint Balancing the harms and benefits of early detection of prostate cancer
    Pim J van Leeuwen
    Erasmus University Medical Center, Rotterdam, Netherlands
    Cancer 116:4857-65. 2010
    ..The benefits of prostate cancer screening on an individual level remain unevaluated...
  50. ncbi request reprint Should prostate-specific antigen screening be offered to asymptomatic men?
    Heidi A van Vugt
    Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands
    Expert Rev Anticancer Ther 10:1043-53. 2010
    ..Algorithms that advise screening at a young age (<55 years), with screening intervals of less than 4 years and low PSA thresholds (<3 ng/ml) for prostate biopsy seem premature and are not supported by evidence...
  51. ncbi request reprint Screening for prostate cancer: have we resolved the controversy?
    Xiaoye Zhu
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    Curr Opin Support Palliat Care 4:121-6. 2010
    ..Implications of these studies will also be underlined...
  52. doi request reprint Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection
    Flip H Jansen
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 57:921-7. 2010
    ..Novel markers for prostate cancer (PCa) detection are needed. Total prostate-specific antigen (tPSA) and percent free prostate-specific antigen (%fPSA=tPSA/fPSA) lack diagnostic specificity...
  53. pmc Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam
    Elisabeth M Wever
    Department of Public Health, Erasmus Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    J Natl Cancer Inst 102:352-5. 2010
    ..26 in the United States vs 0.94 in ERSPC-Rotterdam. We conclude that the efficacy of PSA screening in detecting prostate cancer was lower in the United States than in ERSPC-Rotterdam...
  54. doi request reprint Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?
    Roderick C N van den Bergh
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Cancer 116:1281-90. 2010
    ..Delay before radical treatment caused by active surveillance may be associated with an impaired chance of curability...
  55. doi request reprint Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator
    Heidi A van Vugt
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur J Cancer 46:669-77. 2010
    ..uroweb.org) was developed. This risk indicator is embedded in a leaflet that informs men about the pros and cons of PCa screening and enables calculation of the individual risk of having a biopsy detectable PCa...
  56. ncbi request reprint Anxiety and distress during active surveillance for early prostate cancer
    Roderick C N van den Bergh
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Cancer 115:3868-78. 2009
    ..In this study, these feelings were quantified, and their associations with various psychologic, medical, demographic, and decision-related factors were assessed...
  57. ncbi request reprint Disease insight and treatment perception of men on active surveillance for early prostate cancer
    Roderick C N van den Bergh
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    BJU Int 105:322-8. 2010
    ..Study Type - Survey (prospective cohort) Level of Evidence 1b...
  58. ncbi request reprint Predictive models in diagnosing indolent cancer
    Chris H Bangma
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer 115:3100-6. 2009
    ..Those nomograms based on screening series of the general population need further validation before generalized application is feasible. Cancer 2009;115(13 suppl):3100-6. (c) 2009 American Cancer Society...
  59. ncbi request reprint Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, Netherlands
    Cancer 110:2218-21. 2007
    ..Not all cancers deserve immediate treatment. It has therefore become more important to be able to identify those cases of screen-detected prostate cancer most likely to show indolent behavior...
  60. ncbi request reprint Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 67:1053-60. 2007
    ..We present a feasibility study and impact simulation of a secondary analysis, which imitates a situation where all participants in the study are managed according to their random assignment...
  61. ncbi request reprint Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 51:1244-50; discussion 1251. 2007
    ..To study active surveillance as a management option for the important number of prostate cancer patients who would not have been diagnosed in the absence of screening...
  62. ncbi request reprint Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 67:154-61. 2007
    ..To compare tumor characteristics of screen-detected prostate cancers (PCs) either by digital rectal examination (DRE) or by prostate-specific antigen (PSA) as biopsy indication at low PSA...
  63. ncbi request reprint Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC)
    Stijn Roemeling
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 66:1076-81. 2006
    ..This report compares the preliminary outcome of cancers detected in the screen and the control arm of its Rotterdam section, by means of biochemical progression rates...
  64. ncbi request reprint Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population
    Stijn Roemeling
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    J Urol 175:1332-6. 2006
    ..The clinical presentation and prognosis of familial disease remain uncertain. In this study these entities are evaluated in the first and second rounds of a screening program in The Netherlands...
  65. ncbi request reprint Does PSA velocity predict prostate cancer in pre-screened populations?
    Fritz H Schroder
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 49:460-5; discussion 465. 2006
    ..An elevated PSA in secondary screens may indicate benign enlargement of the prostate rather than prostate cancer. In such cases the yearly rate of increase of PSA (PSA velocity [PSAV]) may improve the test characteristics of PSA...
  66. ncbi request reprint Tumour features in the control and screening arm of a randomized trial of prostate cancer
    Renske Postma
    Department of Pathology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 50:70-5. 2006
    ..To compare tumour characteristics at the time of diagnosis of cancers detected in the screening and control arm at the Rotterdam section of the European Randomized study of Screening for Prostate Cancer...
  67. ncbi request reprint Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement
    Fritz H Schroder
    Department of Urology, Erasmus MC Rotterdam, The Netherlands
    Eur Urol 48:922-30; discussion 930-1. 2005
    ..The present tertiary prevention study reports on the effect of a dietary supplement in comparison with placebo on the rate of increase of prostate-specific antigen (PSA)...
  68. ncbi request reprint Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years
    Rensbe Postma
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer 103:708-16. 2005
    ....
  69. ncbi request reprint Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years?
    Tineke Wolters
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    BJU Int 101:283-8. 2008
    ..To identify pathological features in non-malignant sextant prostate needle biopsies and assess their predictive value for detecting prostate cancer on biopsy 4 years later...
  70. doi request reprint Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC
    Fritz H Schroder
    Department of Urology, Erasmus MC, University Medical Centre Rotterdam, The Netherlands
    Eur Urol 53:901-8. 2008
    ..0 ng/ml were not biopsied (with few exceptions). In the Prostate Cancer Prevention Trial (PCPT) eligible men who initially presented with PSA values <3.0 ng/ml were all biopsied during or at the end of a 7-yr study period...
  71. doi request reprint The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison
    Roderick C N van den Bergh
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    BJU Int 102:1068-73. 2008
    ....
  72. doi request reprint Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer
    Fritz H Schroder
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    Curr Opin Urol 19:227-31. 2009
    ..There is uncertainty about its proper use in diagnosing prostate cancer. This review describes the background of the addressed problem and summarizes relevant, recent findings reported during 2008...
  73. doi request reprint Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly
    Roderick C N van den Bergh
    Department of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Eur Urol 55:1-8. 2009
    ..Many of these cancers will not progress, and radical therapy may lead to substantial overtreatment. Active surveillance (AS) has emerged as an alternative...
  74. ncbi request reprint Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?
    Claartje Gosselaar
    Department of Urology Screening unit for prostate cancer, Erasmus University, Rotterdam, The Netherlands
    BJU Int 95:231-7. 2005
    ..The favourable characteristics of tumours detectable at very low PSA levels seem to justify the conclusion that an unknown but sizeable proportion of the cancers found at biopsy are clinically insignificant...
  75. ncbi request reprint The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 54:581-8. 2008
    ..The value of digital rectal examination (DRE) as a screening test for prostate cancer (PC) is controversial in the current prostate-specific antigen (PSA) era...
  76. doi request reprint Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 55:139-46. 2009
    ..Evidence indicates that an abnormal digital rectal examination (DRE) is a risk factor for high-grade prostate cancer (PC)...
  77. doi request reprint Defining increased future risk for prostate cancer: evidence from a population based screening cohort
    Fritz H Schroder
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    J Urol 181:69-74; discussion 74. 2009
    ..We examined the population risk during 4 years, defined a prostate specific antigen associated with this risk and clarified the contribution of other predictive factors...
  78. doi request reprint Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam)
    Tineke Wolters
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Eur Urol 55:385-92. 2009
    ..The value of prostate-specific antigen velocity (PSAV) in screening for prostate cancer (PCa) and especially for clinically significant PCa is unclear...
  79. ncbi request reprint The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    BJU Int 101:685-90. 2008
    ..To determine the value of a hypoechoic lesion (HL)-directed biopsy in addition to a systematic sextant biopsy for detecting prostate cancer...
  80. doi request reprint Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men
    Roderick C N van den Bergh
    Department of Urology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BJU Int 103:1472-7. 2009
    ..CONCLUSION In selected patients with screen-detected Gleason 3 + 4 = 7 prostate cancer, AS might be an option, especially in those with comorbidity and/or a short life-expectancy...
  81. doi request reprint A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial
    Tineke Wolters
    Department of Pathology, Erasmus MC Rotterdam, The Netherlands
    J Urol 185:121-5. 2011
    ..5 ml for the index tumor. In this study we reassess this tumor volume threshold for clinically insignificant prostate cancer using an independent data set...
  82. doi request reprint Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam
    Meelan Bul
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    Eur Urol 59:498-505. 2011
    ..The European Randomised Study of Screening for Prostate Cancer (ERSPC) applies a prostate-specific antigen (PSA) cut-off value ≥3.0 ng/ml as an indication for lateralised sextant biopsy...
  83. doi request reprint Prediction of prostate cancer in unscreened men: external validation of a risk calculator
    Heidi A van Vugt
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur J Cancer 47:903-9. 2011
    ..Prediction models need external validation to assess their value beyond the setting where the model was derived from...
  84. doi request reprint Blinded and uniform causes of death verification in cancer screening: a major influence on the outcome of a prostate cancer screening trial?
    S J Otto
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Eur J Cancer 46:3061-7. 2010
    ....
  85. doi request reprint Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer
    S J Boevee
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    Eur J Cancer 46:3082-9. 2010
    ....
  86. ncbi request reprint A framework for the identification of men at increased risk for prostate cancer
    Monique J Roobol
    Department of Urology, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands
    J Urol 182:2112-20. 2009
    ....
  87. ncbi request reprint Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam
    Ingrid W van der Cruijsen-Koeter
    Departments of Urology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    J Urol 174:121-5. 2005
    ..This report provides a comparison of characteristics detected in the screening and control arms of the European Randomized study of Screening for Prostate Cancer, section Rotterdam...
  88. ncbi request reprint Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness
    Rene Raaijmakers
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    J Urol 171:2245-9. 2004
    ..0 to 3.9 ng/ml and assessed the value of percent free (F) PSA (FPSA) on tumor detection and tumor aggressiveness in this low PSA range...
  89. ncbi request reprint Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics
    Fritz H Schroder
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 53:468-77. 2008
    ..Screening for PCa has not yet been shown to lower PCa mortality. Still, opportunistic screening is wide spread in Europe and in most other parts of the world...
  90. ncbi request reprint Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam
    Claartje Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 66:625-31. 2006
    ..0 ng/ml and/or abnormal DRE/TRUS (group-1) to solely a PSA cut-off of 3.0 ng/ml (group-2). We estimated the effect of omitting DRE/TRUS by comparing the results of a re-screening 4 years after initial screening to the original policy...
  91. ncbi request reprint Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program
    Rene Raaijmakers
    Department of Urology, Academic Hospital Dijkzigt, Rotterdam, The Netherlands
    Urology 60:826-30. 2002
    ..Biopsy of the prostate has to be a relatively safe procedure and the participants have to be well informed about the possible complications...
  92. ncbi request reprint Detection characteristics in randomized prostate screening
    Fritz H Schroder
    Clin Cancer Res 10:5641-2. 2004
  93. ncbi request reprint Rotterdam randomized pilot studies of screening for prostate cancer--an overview after 10 years
    Fritz H Schroder
    J Natl Cancer Inst 97:696. 2005
  94. ncbi request reprint Prostate cancer in the Swedish section of ERSPC--evidence for less metastases at diagnosis but not for mortality reduction
    Fritz H Schroder
    Eur Urol 51:588-90. 2007
  95. doi request reprint Re: Is a screening interval of every 4 years for prostate cancer acceptable?
    Monique J Roobol
    J Natl Cancer Inst 100:222; author reply 223-4. 2008
  96. ncbi request reprint Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam
    Ingrid W van der Cruijsen-Koeter
    Department of Urology, Josephine Nefkens Institute, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    Urology 68:615-20. 2006
    ....
  97. ncbi request reprint Prospective validation of active surveillance in prostate cancer: the PRIAS study
    Roderick C N van den Bergh
    Eur Urol 52:1560-3. 2007